zmanindc, If AMRN is acquired the litigation can still proceed under the AMRN name if the BP thinks that would make a difference. My point was to keep in mind that delays of a prospective buyout will only result in AMRN being worth less money as the value comes from the commercial life of Vascepa in the various jurisdictions where it is approved. AMRN desperately needs solid, competent management and sales reps who are the creme of the creme. Sorry, but JT needs to be gone. (My biggest fear is that JT will be unwilling to sell his "baby" to BP.)
Market Data 
Markets 
AI
